Statute Details
- Title: Human Biomedical Research (Restricted Research) Regulations 2017
- Legislative Instrument Type: Subsidiary Legislation (SL)
- Authorising Act: Human Biomedical Research Act 2015 (Section 63)
- Act Code: HBRA2015-RG2
- Revised Edition: 2025 Revised Edition (2 June 2025)
- Commencement (original): 1 November 2017 (SL 622/2017)
- Most Recent Amendment (noted in timeline): S 390/2023 (26 June 2023)
- Status: Current version as at 27 March 2026
- Parts: Part 1 (Preliminary), Part 2 (Approval and Conduct of Restricted Research in General), Part 3 (Research Involving Oocytes and Embryos), Part 4 (Miscellaneous)
- Key Provisions (from extract): Section 2 (Definitions); Sections 3–8 (general approval and conduct); Sections 9–15 (oocytes/embryos); Sections 16–17 (electronic system and false information)
What Is This Legislation About?
The Human Biomedical Research (Restricted Research) Regulations 2017 (“Restricted Research Regulations”) form a regulatory framework under Singapore’s Human Biomedical Research Act 2015. In plain terms, they set out how researchers and research institutions must seek approval and conduct “restricted human biomedical research” (a category of higher-risk or more sensitive research) in a controlled and ethically supervised manner.
The Regulations are particularly important because they do not merely require general research ethics oversight. They impose specific procedural and substantive constraints on approvals, consent-taking, and ongoing compliance. They also contain a dedicated set of rules for research involving oocytes (human eggs) and embryos—reflecting the heightened ethical and legal sensitivity of work that affects human reproductive cells and early human life stages.
Practically, the Regulations aim to ensure that restricted research is (i) properly authorised before it begins, (ii) conducted strictly within the scope of the approved application, (iii) supported by robust consent processes (including special requirements for donors), and (iv) subject to additional safeguards where embryos and oocytes are involved.
What Are the Key Provisions?
1. Definitions and the regulatory trigger (Part 1)
The Regulations begin with definitions that anchor the scope of compliance. Section 2 defines, among other terms, “assisted reproduction treatment” by reference to the Healthcare Services Act 2020, and “institutional animal care and use committee” by reference to the Animals and Birds (Care and Use of Animals for Scientific Purposes) Rules. It also defines “restricted research” as “any restricted human biomedical research.” While the extract does not reproduce the full definition of “restricted human biomedical research,” the structure indicates that the Regulations operate as a targeted compliance layer for that category.
2. Approval for restricted research (Part 2)
Part 2 governs approval and conduct for restricted research in general. Section 3 addresses approval for restricted research starting on or after 1 November 2017. Section 4 addresses restricted research that started before 1 November 2017, which typically implies a transitional compliance pathway (for example, requiring subsequent authorisation or reporting to bring earlier work into the regulatory regime). For practitioners, the key issue is timing: whether the research commenced before or after the regulatory commencement date can affect the approval route and compliance obligations.
3. Consent-taking and donor protections (Section 5)
Section 5 introduces “special requirements in consent-taking for restricted research.” Although the extract does not set out the detailed consent mechanics, the legislative intent is clear: consent for restricted research must be obtained in a manner that meets heightened standards. In practice, this often means ensuring that participants (or relevant donors) receive additional information about risks, purposes, procedures, and any special implications of the research category.
4. Conditions for conduct, reporting, and strict adherence to approval (Sections 6–8)
Section 6 sets out “conditions for conduct of restricted research.” These conditions are the operational backbone of compliance: they govern how the research must be run, including governance, safeguards, and adherence to ethical and regulatory requirements. Section 7 requires a “report by researcher,” which is a continuing obligation rather than a one-off approval step. Section 8 provides that there must be “no deviation from approved application for restricted research.” This is a critical compliance rule: changes in protocol, scope, methods, participant/donor involvement, or other key elements generally require an amendment/approval pathway rather than informal modification.
5. Oocytes and embryos: a dedicated regulatory regime (Part 3)
Part 3 applies specifically to research involving oocytes and embryos. Section 9 clarifies the scope of this Part, meaning that once the research involves oocytes/embryos, the additional restrictions and procedural requirements apply on top of the general Part 2 framework.
6. Restrictions on embryo growth and further constraints (Sections 10–11)
Section 10 imposes “restrictions on growth of embryo.” This typically limits how long embryos may be cultured or developed in vitro, and/or the stage of development that may be reached. Section 11 adds “further restriction on persons involved in assisted reproduction treatment or other therapy.” This suggests that individuals or clinical contexts associated with assisted reproduction may be subject to additional limitations when their involvement intersects with embryo research—again reflecting heightened ethical safeguards.
7. Consent, cooling-off, and governance for oocyte/embryo donors (Sections 12–14)
Sections 12 and 13 introduce special consent requirements and a “cooling-off period for oocyte and embryo donors.” The cooling-off concept is designed to reduce coercion or undue influence by ensuring donors have time to reflect before consenting to the use of oocytes/embryos for research. Section 14 requires “institutional review board approval” of research involving surplus oocytes and embryos. This is a governance checkpoint: even where oocytes/embryos are “surplus” (for example, no longer needed for reproductive purposes), their use for research must be reviewed and approved by the relevant institutional review board.
8. Release of oocytes or embryos for research (Section 15)
Section 15 governs “release of oocytes or embryos for research.” In practice, this provision is likely to require that release is authorised only under specified conditions—such as valid consent, appropriate approvals, and compliance with the restrictions on development and donor involvement. For counsel advising institutions, Section 15 is often where documentation and chain-of-custody issues become critical: who can release, under what authority, and what records must be maintained.
9. Administrative compliance: electronic systems and false information (Part 4)
Part 4 includes Section 16 on an “electronic system.” This indicates that approvals, submissions, reporting, or related administrative processes may be required to be made through a specified electronic platform. Section 17 prohibits “false information.” This is a standard but high-stakes compliance provision: providing false or misleading information in applications, reports, or submissions can undermine authorisation and may expose researchers and institutions to enforcement consequences under the broader Human Biomedical Research framework.
How Is This Legislation Structured?
The Regulations are organised into four parts:
Part 1 (Preliminary) contains the citation and definitions (including key terms such as “restricted research,” and cross-references to other Singapore regulatory regimes).
Part 2 (Approval and Conduct of Restricted Research in General) sets out how restricted research is authorised (including transitional rules), how consent must be taken, the conditions for conduct, reporting duties, and the strict “no deviation” rule from the approved application.
Part 3 (Research Involving Oocytes and Embryos) provides additional, more stringent rules for embryo/oocyte research, including restrictions on embryo growth, further constraints relating to persons involved in assisted reproduction treatment, special consent and cooling-off requirements, institutional review board approval for surplus oocytes/embryos, and rules on release for research.
Part 4 (Miscellaneous) addresses administrative mechanisms (electronic system) and integrity requirements (false information).
Who Does This Legislation Apply To?
The Regulations apply to parties involved in conducting restricted human biomedical research in Singapore—most directly, research institutions and researchers who seek approval to start or continue such research. Because the Regulations also refer to institutional review boards and donor consent processes, they affect governance bodies and clinical/assisted reproduction contexts where oocytes and embryos are sourced.
Where research involves oocytes or embryos, the Regulations also apply to oocyte and embryo donors (through consent and cooling-off requirements) and to persons connected with assisted reproduction treatment or other therapy (through additional restrictions on involvement). The practical takeaway is that compliance is not limited to the laboratory: it extends to clinical workflows, consent documentation, and institutional oversight.
Why Is This Legislation Important?
For practitioners, the Restricted Research Regulations are important because they translate the Human Biomedical Research Act 2015’s high-level policy goals into concrete, operational compliance duties. The “approval first” approach (Sections 3–4), the “special consent” requirements (Section 5), and the “no deviation” rule (Section 8) collectively mean that institutions must treat restricted research as a tightly controlled regulatory category rather than ordinary research activity.
The Part 3 regime is especially significant. Embryo and oocyte research often involves complex ethical considerations, multiple stakeholders, and sensitive clinical processes. The Regulations’ restrictions on embryo growth (Section 10), constraints on persons involved in assisted reproduction (Section 11), and donor protections (Sections 12–13) create a structured pathway that aims to prevent rushed or ethically compromised consent and to limit the extent of embryo development for research purposes.
Finally, the administrative provisions on electronic systems (Section 16) and false information (Section 17) underscore that compliance is also about process integrity. Counsel advising institutions should therefore focus not only on substantive ethics, but also on documentation, submission accuracy, audit trails, and change control—especially where protocols evolve during the research lifecycle.
Related Legislation
- Human Biomedical Research Act 2015 (authorising Act; including the broader enforcement and regulatory framework)
- Healthcare Services Act 2020 (definition reference for “assisted reproduction treatment”)
- Animals and Birds (Care and Use of Animals for Scientific Purposes) Rules (definition reference for institutional animal care and use committee)
Source Documents
This article provides an overview of the Human Biomedical Research (Restricted Research) Regulations 2017 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.